Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI3011 in Healthy Subjects and Acute Gout Flare
NCT07295496Phase 1Active, not recruiting
- Sponsor
- Innovent Biologics
- Start
- Dec 2025
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised trial in gout comparing IBI3011 with Placebo (2 arms). Primary endpoint: Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) at 12 weeks. Started Dec 2025; status: active, not recruiting.
02
Drugs
IBI3011
03
Conditions
gout
Beyond the preview
Go deeper on NCT07295496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07295496.